Your browser is no longer supported. Please, upgrade your browser.
Settings
OGEN Oragenics, Inc. daily Stock Chart
OGEN [NYSE]
Oragenics, Inc.
Index- P/E- EPS (ttm)-1.36 Insider Own0.90% Shs Outstand47.02M Perf Week4.37%
Market Cap23.48M Forward P/E- EPS next Y-0.23 Insider Trans0.00% Shs Float43.39M Perf Month1.94%
Income-11.30M PEG- EPS next Q-0.06 Inst Own24.00% Short Float4.66% Perf Quarter-45.12%
Sales- P/S- EPS this Y36.40% Inst Trans215.59% Short Ratio1.24 Perf Half Y-42.60%
Book/sh0.74 P/B0.67 EPS next Y14.80% ROA-67.60% Target Price2.25 Perf Year-57.32%
Cash/sh0.62 P/C0.80 EPS next 5Y- ROE-119.10% 52W Range0.38 - 3.74 Perf YTD-41.85%
Dividend- P/FCF- EPS past 5Y24.80% ROI- 52W High-87.02% Beta1.59
Dividend %- Quick Ratio14.20 Sales past 5Y- Gross Margin- 52W Low27.76% ATR0.04
Employees12 Current Ratio14.20 Sales Q/Q- Oper. Margin- RSI (14)43.50 Volatility12.84% 7.98%
OptionableNo Debt/Eq0.00 EPS Q/Q74.40% Profit Margin- Rel Volume0.32 Prev Close0.50
ShortableYes LT Debt/Eq0.00 EarningsMay 21 Payout- Avg Volume1.63M Price0.49
Recom2.00 SMA20-4.97% SMA50-15.37% SMA200-39.73% Volume414,000 Change-2.78%
May-20-19 07:45AM  Oragenics, Inc. Provides Development Update of AG013 for Oral Mucositis Business Wire +15.86%
May-13-19 09:07AM  Newly Published Preclinical Data on Oragenics, Inc.s Lantibiotic Compound Demonstrates Tolerability and Compartmentalization to the GI Tract Business Wire
Apr-24-19 12:00PM  Introducing Oragenics (NYSEMKT:OGEN), The Stock That Collapsed 98% Simply Wall St.
Apr-04-19 10:00AM  OGEN: 60th Patient Enrolled into Phase 2 Trial of AG013; Data in 1H2020 Zacks Small Cap Research
Mar-28-19 08:00AM  Oragenics, Inc. to Present at Spring Investor Summit on April 1, 2019 Business Wire +6.46%
Mar-27-19 08:00AM  Oragenics, Inc. Enters into Collaboration with Florida International University to Expand Its Pipeline of Lantibiotics Business Wire
Mar-25-19 04:00PM  Oragenics Announces Closing of $12.5 Million Underwritten Public Offering Business Wire
Mar-21-19 06:00AM  Oragenics Announces Pricing of $12.5 Million Underwritten Public Offering Business Wire -30.29%
Mar-20-19 05:16PM  6 Stocks Moving In Wednesday's After-Hours Session Benzinga
04:40PM  Organics Announces Proposed Underwritten Public Offering Business Wire
Mar-18-19 02:00PM  Four Healthcare Stocks Heating Up On Monday ACCESSWIRE +7.60%
Mar-15-19 04:17PM  Oragenics, Inc. Announces Enrollment of 60th Patient in Clinical Trial Business Wire
12:00AM  Oragenics Inc. to Attend the Roth Capital 31st Annual Growth Conference March 17 - 19, 2019 Business Wire
Feb-22-19 07:32AM  How Much Are Oragenics, Inc. (NYSEMKT:OGEN) Insiders Spending On Buying Shares? Simply Wall St.
Jan-31-19 01:15PM  OGEN: New Preclinical Research Confirms OG716 Potential in Treating C. Difficile Infection Zacks Small Cap Research
Jan-28-19 08:37AM  Oragenics, Inc. Receives Further Validation for Lantibiotic Compound OG716 Business Wire
Jan-25-19 01:45PM  Oragenics Inc. to Present at NobleCon15 on January 28, 2019 Business Wire
Dec-03-18 07:05AM  Oragenics Fast Track Drug AG013 Going into Phase II Clinicals, Pipeline Review ACCESSWIRE -5.19%
06:50AM  Today's Research Reports on Trending Tickers: Oragenics and Intec Pharma ACCESSWIRE
Nov-27-18 08:30AM  Oragenics, Inc. Announces Publication Detailing the Development of Blueprints for Designing a New Class of Anti-Infectives Business Wire
Nov-26-18 03:30PM  Oragenics, Inc. to Present at the 11th Annual LD Micro Main Event ACCESSWIRE
08:45AM  Recent Analysis Shows Liberty Global, New Oriental Education & Technology Group, Platinum Group Metals, Asure Software, Oragenics, and MGE Energy Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-19-18 12:15PM  OGEN: Phase 2 Trial of AG013 Adds Clinical Sites in Europe Zacks Small Cap Research -6.38%
Nov-15-18 04:15PM  Oragenics, Inc. Receives Clearance to Enroll Patients in Germany and the United Kingdom into Its Phase 2 Clinical Trial of AG013 for Oral Mucositis Business Wire +6.70%
Nov-14-18 07:27PM  Oragenics, Inc. Announces 3Q 2018 Financial Results and Provides Corporate Update Business Wire -14.43%
Nov-13-18 07:27PM  Oragenics: 3Q Earnings Snapshot Associated Press
Oct-30-18 11:15AM  Positive Global Healthcare Outlook Could Push 3 Stocks Higher ACCESSWIRE +30.12%
Oct-18-18 08:00AM  Todays Research Reports on Stocks to Watch: Fresenius Medical Care and Oragenics ACCESSWIRE -7.20%
Oct-17-18 07:30AM  Oragenics, Inc. Receives Clearance to Enroll Patients in Belgium into Its Phase 2 Clinical Trial of AG013 for Oral Mucositis Business Wire +9.65%
Oct-12-18 08:00AM  Today's Research Reports on Trending Tickers: Oragenics and ACADIA Pharmaceuticals ACCESSWIRE -6.72%
Oct-10-18 10:30AM  This Weeks Biotech and Cannabis Stocks to Watch ACCESSWIRE -21.21%
Oct-05-18 12:05PM  Should You Worry About The Oragenics Incs (NYSEMKT:OGEN) Shareholder Register? Simply Wall St.
Oct-04-18 10:30AM  These Stocks Are on The Brink of Breakouts ACCESSWIRE -13.71%
08:19AM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Oragenics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
Oct-02-18 10:30AM  Biotech Market is Rolling and These Companies Need to Be on Your Radar ACCESSWIRE +123.12%
Sep-25-18 07:45AM  Oragenics, Inc. to Present at Upcoming Conferences in October Business Wire -35.48%
Sep-24-18 08:00AM  Todays Research Reports on Stocks to Watch: Oragenics and Pfizer ACCESSWIRE +29.17%
07:20AM  Can Oragenics Inc (NYSEMKT:OGEN) Improve Your Portfolio Returns? Simply Wall St.
Sep-17-18 03:49PM  Have Investors Priced In Healthcare Growth For Oragenics Inc (NYSEMKT:OGEN)? Simply Wall St.
09:13AM  Oragenics, Inc. to Present Data from Its Lantibiotics Program at the Boulder Peptide Symposium Monday, September 24, 2018 Business Wire
Aug-17-18 01:30PM  OGEN: Positive DSMB Review for Phase 2 Trial of AG013 Zacks Small Cap Research
Aug-15-18 07:30AM  Oragenics, Inc. Resumes Phase 2 Clinical Trial of AG013 in Oral Mucositis Following Positive Routine Safety Review Business Wire
Jul-27-18 07:55AM  Free Pre-Market Technical Pulse on Sesen Bio and Three More Biotech Stocks ACCESSWIRE
Jul-20-18 09:30AM  OGEN: Raises Net Proceeds of $12.3 Million in Underwritten Public Offering Zacks Small Cap Research -7.98%
Jul-17-18 04:15PM  Oragenics, Inc. Announces Closing of $13.8 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option Business Wire -9.24%
Jul-13-18 08:16AM  Oragenics, Inc. Announces Pricing of $12 Million Underwritten Public Offering Business Wire -34.43%
Jun-27-18 07:20AM  Free Technical Research on Nektar Therapeutics and Three More Biotech Equities ACCESSWIRE
Jun-20-18 09:30AM  Diamond Equity Research Initiates Coverage on Oragenics Inc. (NYSE:OGEN) with a Valuation of $3.50 Per Share GlobeNewswire +11.64%
Jun-13-18 08:30AM  Oragenics, Inc. Announces Peer-Reviewed Publication Detailing Discovery of OG716 for C. difficile infections Business Wire
Jun-11-18 10:30AM  OGEN: Initiating Coverage of Oragenics, Inc.; Developing a Novel Class of Antibiotics and Treatment for Oral Mucositis Zacks Small Cap Research
Jun-05-18 12:26PM  Is Oragenics Incs (NYSEMKT:OGEN) CEO Paid At A Competitive Rate? Simply Wall St. +7.14%
May-31-18 08:20AM  Todays Research Reports on Stocks to Watch: Oragenics and Sigma Labs ACCESSWIRE -25.00%
May-30-18 07:30AM  Oragenics Reports Positive Interim Safety Analysis Results from Its Phase 2 Clinical Trial of AG013 for Oral Mucositis Business Wire +66.67%
May-29-18 07:20AM  Nektar Therapeutics and Three Additional Biotech Stocks on Our Research Desks Radar ACCESSWIRE
May-23-18 02:00PM  Oragenics, Inc. and Texas A&M University System Granted U.S. Patent for Lantibiotic MU1140 Business Wire +19.66%
Apr-20-18 07:38PM  Who Are The Top Investors In Oragenics Inc (NYSEMKT:OGEN)? Simply Wall St.
Apr-13-18 12:31PM  Does Oragenics Inc (NYSEMKT:OGEN) Fall With The Market? Simply Wall St.
Apr-06-18 02:25PM  Oragenics, Inc. Announces Pricing of $1.8 Million Registered Direct Offering Business Wire
Mar-23-18 08:30PM  Oragenics Completes Enrollment for the Interim Analysis Cohort in Its Phase 2 Clinical Trial of AG013 for Oral Mucositis Business Wire
Mar-19-18 07:30AM  Oragenics, Inc. Announces Peer Reviewed Publication Examining Efficacy of Mutacin 1140 Lantibiotic Variants against Clostridium difficile Business Wire +9.45%
Mar-12-18 12:06PM  Did Oragenics Incs (NYSEMKT:OGEN) Earnings Growth Outperform The Industry? Simply Wall St. -11.49%
Mar-06-18 03:18PM  Oragenics, Inc. to Present at The MicroCap Conference on April 9th and 10th in New York City at the Essex House ACCESSWIRE +9.60%
Feb-20-18 04:15PM  Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation Business Wire
Jan-08-18 07:15AM  Oragenics, Inc. Announces Reverse Stock Split Business Wire -23.27%
Nov-28-17 09:36AM  Oragenics Inc (OGEN) Earnings: Did It Outperform The Industry? Simply Wall St.
Nov-13-17 07:00AM  Oragenics, Inc. Regains Compliance with NYSE American Continued Listing Standards Business Wire
Nov-09-17 07:00AM  Oragenics Announces Closing of $3.3 Million Preferred Stock Private Placement and $3.4 Million Debt Conversion into Equity Business Wire
Oct-27-17 01:41PM  Oragenics Inc (OGEN): Time For A Financial Health Check Simply Wall St.
Sep-28-17 09:25AM  Is Oragenics Inc (OGEN) A Good Healthcare Bet? Simply Wall St.
Sep-06-17 06:49PM  Oragenics to Present at the 19th Annual Rodman & Renshaw Global Investment Conference Business Wire
Aug-31-17 07:30AM  Oragenics Doses First Patient in Phase 2 Clinical Trial of AG013 for Oral Mucositis Business Wire
Aug-14-17 07:32PM  Oragenics reports 2Q loss Associated Press +9.03%
Jul-26-17 07:45AM  Oragenics Announces Completion of Second Closing of $3.0 Million Preferred Stock Private Placement Business Wire
Jun-09-17 05:00PM  Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE MKT Continued Listing Standard Business Wire
Jun-06-17 06:47PM  Oragenics Presents Development of Novel Lantibiotic Against Clostridium difficile at the ICAAC Conference Business Wire
May-16-17 12:18PM  How these two Tampa Bay companies got the financing to grow their technology American City Business Journals +16.16%
May-11-17 12:38PM  CORRECTION FROM SOURCE: Dawson James Securities Acts as Financial Advisor to Oragenics, Inc. on $3.4m Preferred Stock Private Placement and $2.4m Loan Accesswire
12:10PM  Dawson James Securities Acts as Financial Advisor to Oragenics, Inc. on $3.4m Preferred Stock Private Placement and $2.4m Loan Accesswire
07:45AM  Oragenics Announces $3.0 Million Preferred Stock Private Placement and $2.4 Million Loan Business Wire
Apr-18-17 01:12PM  Oragenics Provides First Quarter 2017 Update Business Wire
Mar-03-17 04:45PM  Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation Business Wire
01:04PM  ORAGENICS INC Financials
Mar-01-17 05:10PM  Intrexon Announces Fourth Quarter and Full Year 2016 Financial Results PR Newswire
Feb-27-17 04:11PM  ORAGENICS INC Files SEC form 10-K, Annual Report
Jan-31-17 05:17PM  ORAGENICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Jan-04-17 07:45AM  Oragenics Shareholder Update Business Wire
Dec-15-16 07:45AM  Oragenics Presents Engineering of Improved Lantibiotic Variants at American Society for Microbiology (ASM) Conference on Antibacterial Development Business Wire
Nov-23-16 10:16AM  Oragenics AG013 Drug Gets Fast Track Status (OGEN) Investopedia
10:16AM  Oragenics AG013 Drug Gets Fast Track Status (OGEN) at Investopedia
08:18AM  Oragenics Jumps on Fast Track Status for Oral Mucositis Drug Zacks
Nov-22-16 05:59AM  Oragenics Practically Doubles on FDA Decision 24/7 Wall St.
Nov-21-16 03:29PM  U.S. FDA Grants Fast Track Designation for the Development of Oragenics AG013 for Oral Mucositis Business Wire
09:01AM  ORAGENICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Nov-14-16 05:45PM  ORAGENICS INC Files SEC form 10-Q, Quarterly Report
Sep-15-16 03:18PM  ORAGENICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Aug-30-16 04:08PM  ORAGENICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Secur
08:15AM  Oragenics Receives Supportive FDA Feedback for Initiating a Phase 2 Study Protocol for Oral Mucositis Treatment Business Wire
Aug-26-16 02:42PM  Tampa biopharmas $30M capital raise could aid people with infections, cancer at bizjournals.com
Aug-23-16 08:44AM  ORAGENICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:15AM  Oragenics Selects New Lantibiotic for Further Development in Clostridium difficile Infections Business Wire
Oragenics, Inc. develops novel antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring chemical agent for use in weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay. Oragenics, Inc. has collaboration agreements with Intrexon Corporation and its subsidiary, Intrexon Actobiotics NV to develop AG013; a license agreement with LPThera LLC to develop LPT3-04; and a license agreement Texas A&M University System for access to new homologs of the lantibiotic MU1140 and other lantibiotics. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KOSKI FAMILY LP10% OwnerSep 18Buy0.4122,0009,009277,839Sep 18 04:07 PM
KOSKI FAMILY LP10% OwnerSep 17Buy0.42100,00042,000255,839Sep 18 04:07 PM
KOSKI FAMILY LP10% OwnerSep 14Buy0.4247,05019,718155,839Sep 18 04:07 PM